Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Emergency use Authorization and what it would mean for CLAS

<< Previous

Bullboard Posts

Next >>

Comment by Whyme16on Aug 24, 2021 3:55pm

94 Views

Post# 33756007

RE:Emergency use Authorization and what it would mean for CLAS

This would be applicable to a REAL company that has a reputation to actually DELIVER! When was the last time this company delivered smething of value?? Phase 1 completion has already been delayed to EARLY 2022 (THIS WAS SUPPOSED TO COMPLETE IN 2021). By the time pahse 2a is completed late 2022 this drug will either be irrelevant OR licence transfered to some other company due to Bob's incompetence and side-deals just like GHVO program. BOB HAS TO RESIGN AND THAT WOULD BE OUR ONLY HOPE OF SURVIVAL.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario